Prognostic Value and Immunological Role of P4HA3 in Colon Adenocarcinoma

References

• Tian Y, Kharazmi E, Brenner H, et al. Calculating the starting age for screening in relatives of patients with colorectal cancer based on data from large nationwide data sets. Gastroenterology. 2020;159(1):159–168.e3. doi:10.1053/j.gastro.2020.03.063
   PubMed Web of Science ®Google Scholar
• Zhou XG, Huang XL, Liang SY, et al. Identifying miRNA and gene modules of colon cancer associated with pathological stage by weighted gene co-expression network analysis. Onco Targets Ther. 2018;11:2815–2830. doi:10.2147/OTT.S163891
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565
   PubMed Web of Science ®Google Scholar
• Liu N, Wu C, Jia R, et al. Traditional Chinese medicine combined with chemotherapy and cetuximab or bevacizumab for metastatic colorectal cancer: a randomized, double-blind, placebo-controlled clinical trial. Front Pharmacol. 2020;11:478. doi:10.3389/fphar.2020.00478
   PubMed Web of Science ®Google Scholar
• Andre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMoa2017699
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, Phase 2 study. Lancet Oncol. 2017;18(9):1182–1191. doi:10.1016/s1470-2045(17)30422-9
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x
   PubMed Web of Science ®Google Scholar
• Harding JJ, Dika IE, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: primed to make a difference? Cancer. 2016;122(3):367–377. doi:10.1002/cncr.29769
   PubMed Web of Science ®Google Scholar
• Liu Y, Qiao L, Zhang S, et al. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. Acta Biomater. 2018;66:310–324. doi:10.1016/j.actbio.2017.11.010
   PubMed Web of Science ®Google Scholar
• Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021;27(1):78–86. doi:10.1158/1078-0432.CCR-20-2063
   PubMed Web of Science ®Google Scholar
• Rangachari D, Costa DB. From hope to reality: durable overall survival with immune checkpoint inhibitors for advanced lung cancer. J Clin Oncol. 2019;37(28):2511–2513. doi:10.1200/JCO.19.01207
   PubMed Web of Science ®Google Scholar
• Gorres KL, Raines RT. Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol. 2010;45(2):106–124. doi:10.3109/10409231003627991
   PubMed Web of Science ®Google Scholar
• Shi R, Gao S, Zhang J, et al. Collagen prolyl 4-hydroxylases modify tumor progression. Acta Biochim Biophys Sin. 2021;53(7):805–814. doi:10.1093/abbs/gmab065
   Google Scholar
• Kukkola L, Hieta R, Kivirikko KI, Myllyharju J. Identification and characterization of a third human, rat, and mouse collagen prolyl 4-hydroxylase isoenzyme. J Biol Chem. 2003;278(48):47685–47693. doi:10.1074/jbc.M306806200
   PubMed Web of Science ®Google Scholar
• Zhou T, Erber L, Liu B, Gao Y, Ruan HB, Chen Y. Proteomic analysis reveals diverse proline hydroxylation-mediated oxygen-sensing cellular pathways in cancer cells. Oncotarget. 2016;7(48):79154–79169. doi:10.18632/oncotarget.12632
   PubMedGoogle Scholar
• Murugesan M, Premkumar K. Systemic multi-omics analysis reveals amplified P4HA1 gene associated with prognostic and hypoxic regulation in breast cancer. Front Genet. 2021;12:632626. doi:10.3389/fgene.2021.632626
   PubMed Web of Science ®Google Scholar
• Toss MS, Miligy IM, Gorringe KL, et al. Prolyl-4-hydroxylase alpha subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). Br J Cancer. 2018;119(12):1518–1526. doi:10.1038/s41416-018-0337-x
   PubMed Web of Science ®Google Scholar
• Ning Y, Zheng H, Zhan Y, et al. Overexpression of P4HA1 associates with poor prognosis and promotes cell proliferation and metastasis of lung adenocarcinoma. J Cancer. 2021;12(22):6685–6694. doi:10.7150/jca.63147
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yin Y, Zhao H, et al. P4HA1 regulates human colorectal cancer cells through HIF1alpha-mediated Wnt signaling. Oncol Lett. 2021;21(2):145. doi:10.3892/ol.2020.12406
   PubMed Web of Science ®Google Scholar
• Cao Y, Han Q, Li J, Jia Y, Zhang R, Shi H. P4HA2 contributes to cervical cancer progression via inducing epithelial-mesenchymal transition. J Cancer. 2020;11(10):2788–2799. doi:10.7150/jca.38401
   PubMed Web of Science ®Google Scholar
• Zhu M, Peng R, Liang X, et al. P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene. 2021;40(41):6049–6056. doi:10.1038/s41388-021-02000-3
   PubMed Web of Science ®Google Scholar
• Song H, Liu L, Song Z, Ren Y, Li C, Huo J. P4HA3 is epigenetically activated by slug in gastric cancer and its deregulation is associated with enhanced metastasis and poor survival. Technol Cancer Res Treat. 2018;17:1533033818796485. doi:10.1177/1533033818796485
   Web of Science ®Google Scholar
• Zhou H, Zou J, Shao C, et al. Prolyl 4-hydroxylase subunit alpha 3 facilitates human colon cancer growth and metastasis through the TGF-beta/Smad signaling pathway. Pathol Res Pract. 2022;230:153749. doi:10.1016/j.prp.2021.153749
   PubMed Web of Science ®Google Scholar
• Huang Z, Lai H, Liao J, et al. Upregulation of ADAM12 is associated with a poor survival and immune cell infiltration in colon adenocarcinoma. Front Oncol. 2021;11:729230. doi:10.3389/fonc.2021.729230
   PubMed Web of Science ®Google Scholar
• Yang H, Lin HC, Liu H, et al. A 6 lncRNA-based risk score system for predicting the recurrence of colon adenocarcinoma patients. Front Oncol. 2020;10:81. doi:10.3389/fonc.2020.00081
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–779. doi:10.1200/JCO.2017.76.9901
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Angell HK, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698–711. doi:10.1016/j.immuni.2016.02.025
   PubMed Web of Science ®Google Scholar
• Dong X, Lv S, Zhang X, Hao R. Upregulation of LAGE3 correlates with prognosis and immune infiltrates in colorectal cancer: a bioinformatic analysis. Int Immunopharmacol. 2020;85:106599. doi:10.1016/j.intimp.2020.106599
   PubMed Web of Science ®Google Scholar
• Pan JH, Zhou H, Cooper L, et al. LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol. 2019;10:6. doi:10.3389/fimmu.2019.00006
   PubMed Web of Science ®Google Scholar
• Wang T, Wang YX, Dong YQ, Yu YL, Ma K. Prolyl 4-hydroxylase subunit alpha 3 presents a cancer promotive function in head and neck squamous cell carcinoma via regulating epithelial-mesenchymal transition. Arch Oral Biol. 2020;113. doi:10.1016/j.archoralbio.2020.104711
   Web of Science ®Google Scholar
• Li Q, Wang Q, Zhang Q, Zhang J, Zhang J. Collagen prolyl 4-hydroxylase 2 predicts worse prognosis and promotes glycolysis in cervical cancer. Am J Transl Res. 2019;11(11):6938–6951.
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8(5):761–773. doi:10.7150/jca.17648
   PubMed Web of Science ®Google Scholar
• Mersakova S, Lasabova Z, Strnadel J, et al. Genomic profile and immune contexture in colorectal cancer-relevance for prognosis and immunotherapy. Clin Exp Med. 2021;21(2):195–204. doi:10.1007/s10238-020-00649-w
   PubMed Web of Science ®Google Scholar
• Picard E, Verschoor CP, Ma GW, Pawelec G. Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol. 2020;11:369. doi:10.3389/fimmu.2020.00369
   PubMed Web of Science ®Google Scholar
• Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195–203. doi:10.1038/nri.2017.145
   PubMed Web of Science ®Google Scholar
• Bess SN, Greening GJ, Muldoon TJ. Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. Cytokine Growth Factor Rev. 2019;49:1–9. doi:10.1016/j.cytogfr.2019.10.002
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909
   PubMed Web of Science ®Google Scholar
• Wang H, Tian T, Zhang J. Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis. Int J Mol Sci. 2021;22(16). doi:10.3390/ijms22168470
   Web of Science ®Google Scholar
• Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147. doi:10.1155/2016/6058147
   PubMed Web of Science ®Google Scholar
• Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M. The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B. 2020;10(11):2156–2170. doi:10.1016/j.apsb.2020.04.004
   PubMed Web of Science ®Google Scholar
• Ge Z, Ding S. The crosstalk between tumor-associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. Front Oncol. 2020;10:590941. doi:10.3389/fonc.2020.590941
   PubMed Web of Science ®Google Scholar
• Yu C, You M, Zhang P, Zhang S, Yin Y, Zhang X. A five-gene signature is a prognostic biomarker in pan-cancer and related with immunologically associated extracellular matrix. Cancer Med. 2021;10(13):4629–4643. doi:10.1002/cam4.3986
   PubMed Web of Science ®Google Scholar